1. NRx amends IND filing for NRX-101 with TMS to treat depression. 2. D-cycloserine enhances TMS efficacy, showing over 80% response rates. 3. Clinical trials expected to validate these promising results. 4. Substantial market potential as over 1 million Americans may use TMS by 2030. 5. NRX-101 has Breakthrough Therapy designation and expanded access policies.
FAQ
Why Bullish?
The strong efficacy data and new commercialization path could drive demand. Historical examples include biotech companies that surged post successful trial results.
How important is it?
The clinical advancements and regulatory support significantly add to NRXP's market outlook.
Why Long Term?
The anticipated regulatory approvals and market growth will unfold over years. Examples include long-term market expansions seen in similar successful treatments.
NRx Pharmaceuticals Amends Investigational New Drug Filing for NRX-101
WILMINGTON, Del., December 03, 2025 (GLOBE NEWSWIRE) – NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, has announced a significant update regarding its investigational product NRX-101. The company has amended its Investigational New Drug (IND) filing to include the use of NRX-101 (D-cycloserine/lurasidone) in conjunction with Transcranial Magnetic Stimulation (TMS) specifically for treating depression, including cases of suicidal depression.
Details of the New Indication for NRX-101
The amendment highlights a promising new indication for NRX-101, which could expedite its pathway to commercialization. Research indicates that NRX-101 may enhance the therapeutic effects of TMS, a non-invasive procedure that utilizes magnetic fields to stimulate brain areas associated with mood regulation.
Recent studies reveal that patients receiving D-cycloserine alongside TMS have reported over a two-fold improvement in depression symptoms compared to those given a placebo. Specifically, a clinical response rate of 75% and a remission rate of 40% were observed in the D-cycloserine-treated cohort.
Supporting Data and Future Trials
On November 4, 2025, additional real-world data was presented, highlighting the efficacy of a modern Theta Burst FDA-cleared TMS device combined with a single oral dose of D-cycloserine. The data showed that 87% of patients experienced a clinical response, with 72% achieving remission by six weeks, assessed via the Hamilton Depression Rating Scale.
If these findings are confirmed through further clinical trials, NRx anticipates that the use of D-cycloserine will become standard care in conjunction with TMS. The efficacy rates observed from TMS with D-cycloserine, which exceed 80%, stand in stark contrast to the 30% success rate currently attributed to SSRI antidepressants, while also avoiding many common side effects associated with these traditional treatments.
Composition and Development Plans
Besides containing D-cycloserine, NRX-101 also incorporates a low dose of lurasidone, an established treatment for depression with known anti-hallucinatory effects. This combination was developed due to concerns about the potential for low-grade hallucinations associated with D-cycloserine, hence leading to its patent protection in all key jurisdictions.
NRx anticipates that forthcoming controlled trials involving approximately 120 participants will further substantiate the clinical benefits unveiled in prior studies. The company is currently in talks with manufacturers of approved TMS devices to establish a joint clinical trial, facilitating the drug registration and enhanced labeling of TMS devices by the FDA.
Market Potential and Future Outlook for NRXP
Looking towards the future, NRx forecasts that upwards of 1 million Americans may be treated with TMS annually by 2030, unveiling a new and substantial market opportunity for NRX-101. As part of its legal obligations for Breakthrough Therapy Drugs like NRX-101, NRx has established an Expanded Access policy to allow eligible patients access to this promising medication.
Healthcare providers interested in learning more about NRX-101 and its potential benefits for patients can reach out to the company for further details.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. specializes in developing therapeutics based on its NMDA platform aimed at central nervous system disorders including suicidal depression, chronic pain, and PTSD. The company is also advancing NRX-100, a preservative-free intravenous ketamine, having secured Fast Track Designation to treat suicidal ideation in various forms of depression. The future trajectory of NRX-101 appears promising, especially given its Breakthrough Therapy Designation for the treatment of suicidal bipolar depression.